Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18344036 | 0.83 | NPC1 (0.44) | NPC1RAB9A | |
| SCHEMBL20296507 | 0.79 | HDAC6 (0.48) | HDAC6PTGES | |
| SCHEMBL29361121 | 0.77 | MAPT (0.51) | HDAC6NPC1RAB9A | |
| SCHEMBL20296406 | 0.76 | HDAC6 (0.53) | HDAC6NPC1RAB9APTGES | |
| SCHEMBL18344035 | 0.76 | ELANE (0.35) | HDAC6NPC1RAB9AELANE | |
| SCHEMBL28821900 | 0.75 | HDAC6 (0.49) | HDAC6PTGES | |
| SCHEMBL20296739 | 0.75 | SLC6A9 (0.41) | NPC1RAB9A | |
| SCHEMBL3468711 | 0.74 | HRH3 (0.52) | HDAC6PTGES | |
| SCHEMBL28821899 | 0.74 | HDAC6 (0.48) | HDAC6NPC1RAB9APTGES | |
| SCHEMBL20296307 | 0.74 | HDAC6 (0.48) | HDAC6NPC1RAB9APTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | HDAC6 303/4885NPC1 3120/4885RAB9A 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.